Moscow, June 4, 2015 - Public Joint Stock Company "Pharmstandard" (LSE: PHST, RTS: PHST RU) (the "Company") announces that it has been informed by Augment Investments Limited ("Augment"), a controlling shareholder of the Company, that Augment waived the Minimum Acceptance Condition of the Tender Offer (when Augment intended to complete the Tender Offer if at least 18,920,276 GDRs representing 4,730,069 Ordinary Shares, which constituted 50% of all GDRs issued and outstanding as of May 11, 2015 are tendered into this Tender Offer) and will accept for purchase and purchase all GDRs validly tendered by the GDR holders prior to the Expiration Time, in accordance with and subject to the remaining conditions set forth in the Tender Offer Memorandum.

Augment waived the Minimum Acceptance Condition following arrangement reached with Bristley that Bristley will not be tendering the Sale GDRs in the Tender Offer but will sell the Sale GDRs to Augment on or prior to July 30, 2015 at a purchase price per GDR equal to the Purchase Price per GDR paid in the Tender Offer.